Eli Lilly shares climbed more than 40% from early August through December 2025 after the company closed its acquisition of Ventyx Biosciences on November 15. The deal secured rights to two next-generation GLP-1 receptor agonists poised to extend Lilly’s leadership in obesity management beyond its current blockbuster therapy. Analysts at CreditHealth projected the combined portfolio could generate incremental annual sales of $12 billion by 2028, bolstering revenue growth forecasts from 10% to 14% over the next three years. The transaction price of $6.5 billion represents a multiple of 18 times estimated 2027 revenue for Ventyx’s pipeline, viewed as accretive to Lilly’s longer-term margin expansion plans. Investor concern over competitive pressure in the weight-loss market eased following detailed integration roadmaps presented at Lilly’s December 4 investor day, which included plans to transition Ventyx’s injectable program to an oral formulation by 2027.

On January 9, Eli Lilly announced a joint investment of $1 billion over five years with Nvidia to establish a co-innovation laboratory focused on AI-driven drug discovery. The lab will be built adjacent to Lilly’s existing R&D campus in the San Francisco Bay Area and will deploy Nvidia’s latest DGX SuperPOD infrastructure to train deep-learning models on datasets exceeding five petabytes. Lilly forecasts that AI-enabled workflows could reduce candidate screening timelines by up to 70% and cut preclinical costs by 30% to 40%, unlocking potential savings of $500 million annually in R&D spend by 2028. The partnership aims to accelerate programs in metabolic disease, oncology and neuroscience, with initial milestones targeting two lead molecules entering clinical trials by late 2026. Credit Suisse analysts upgraded their rating on Lilly to “outperform,” citing improved pipeline visibility and potential revenue upside of $3 billion by 2030.

Late December, the U.S. Food and Drug Administration reported preliminary findings from an ongoing safety review of GLP-1 receptor agonist therapies, including Lilly’s once-weekly obesity treatment. The agency reviewed adverse event reports and clinical trial data totaling over 15,000 patient-years of exposure and found no statistically significant increase in suicidal behaviors compared with placebo. While cautioning that low event rates prevent definitive conclusions, the FDA’s announcement relieved investor fears of a regulatory setback that could have led to additional black-box warnings or label restrictions. In response, Lilly reiterated its post-marketing surveillance plans, which include quarterly safety updates and expanded mental-health screening protocols in clinical trials, further underpinning confidence in continued market uptake and reimbursement discussions with major payers.